ATM revenue +10% but ANZ margin pressure and MVM drag offset China gains

What changed

Revenue rose 10.1% to NZ$893.8m in HY25, accelerating from the 3.7% growth reported in HY24. PBT grew 5.3% to NZ$127.3m and NPAT 7.6% to NZ$91.7m — both directionally positive but running well below the revenue growth rate, indicating margin compression somewhere in the portfolio.

Operating cash flow jumped 26.8% to NZ$78.8m, while capex fell sharply to NZ$2.4m from NZ$12.9m a year earlier, lifting pre-lease free cash flow to NZ$76.4m from NZ$49.2m. Cash conversion improved materially: OCF-to-EBITDA rose to 66.3% from 54.9%.

The balance sheet strengthened further. Cash and term deposits reached NZ$1.04b against gross borrowings of only NZ$66.8m, implying a net cash position of approximately NZ$975m. Total liabilities grew 34.9% to NZ$540.6m — worth monitoring — though this is from a low base and the group remains ungeared.

The company declared its first-ever interim dividend of NZ$0.085 per share; no prior-period dividend existed for comparison.

Segment-level moves tell a mixed story:

• China and Other Asia grew revenue 11.8% to NZ$614.2m and contributed NZ$148.0m of segment EBITDA, but segment margin edged down slightly to approximately 24.1% from 24.7%.
• Australia and New Zealand revenue fell 2.8% to NZ$157.7m with segment EBITDA margin compressing from approximately 21.4% to 18.7%.
• USA revenue grew 13.2% to NZ$64.5m; the segment loss narrowed to NZ$4.9m from NZ$8.3m.
• Mataura Valley Milk (MVM) revenue grew 41.8% to NZ$73.1m but remained deeply loss-making at NZ$11.9m EBITDA loss, though this improved from NZ$15.3m in HY24.

What matters

China concentration and margin trajectory. The China and Other Asia segment generated approximately 68.7% of segment revenue and virtually all of reported group EBITDA profit. The slight margin retreat there (from 24.7% to ~24.1%) is the single most consequential datapoint in the result: at this scale a further step-down would overwhelm any improvement elsewhere. Management cited English label IMF double-digit revenue growth as a key driver, suggesting the recovery in that channel is doing real work — but it also raises the question of how durable that recovery is given the structural decline in China's birth rate.

ANZ deterioration is a quiet red flag. The ANZ segment is the second-largest business but posted a 2.8% revenue decline and a meaningful margin step-down. If ANZ continues to lose ground while management attention is focused on China, it risks becoming a structural drag rather than a stable cash contributor.

Capital allocation inflection point. The maiden dividend at NZ$0.085 per share implies a payout ratio of approximately 67% of NPAT and 80% of pre-lease free cash flow. The NZ$1.04b cash balance makes this trivially affordable, but initiating a dividend signals a shift in the capital allocation framework. It raises an implicit question about whether the balance sheet is being put to productive use, given the size of the net cash position relative to the underlying earnings base.

Expectations

No numeric FY25 guidance range was included in the extraction packet, so a precise tracking exercise against targets is not possible here. Management stated that FY25 full-year revenue and earnings guidance was upgraded, which is directionally consistent with the result.

From a seasonality perspective, FY24 was modestly second-half weighted: HY24 represented approximately 48.5% of FY24 revenue and 48.3% of FY24 EBITDA. Applying that same pattern to HY25 implies a full-year revenue run rate of approximately NZ$1.79b and would require an implied second half of approximately NZ$861m in revenue. That is achievable but not automatic, particularly if ANZ continues to soften and China's English label recovery loses momentum after a re-stocking phase.

The 10.1% revenue growth in HY25 compares favourably to the 5.2% reported for full-year FY24, suggesting the company has re-accelerated. However, the headline growth rate benefits from a relatively modest comparable: HY24 itself grew only 3.7%.

Quality of result

The result has genuine quality components and some caution-worthy ones.

On the positive side: OCF growth of 26.8% outpaced EBITDA growth of 5.0%, inventories were marginally lower year-on-year, and the improvement in OCF-to-EBITDA conversion to 66.3% is credible. The sharp drop in capex (NZ$2.4m versus NZ$12.9m) is the primary driver of the FCF improvement; this is partly timing-driven and should not be extrapolated as a permanent reduction in investment intensity.

On the caution side: EBITDA grew only 5.0% on 10.1% revenue growth, which implies operating leverage is not flowing through as expected. The China segment margin retreated slightly despite strong volume growth, and ANZ margin compression is more pronounced. The effective tax rate eased from 35.0% to 34.0%, which added modestly to NPAT growth — NPAT grew 7.6% versus PBT growth of 5.3%, so the tax line is providing a small flattering effect. There are no non-recurring items identified in the packet, so the result appears to reflect run-rate economics, which makes the margin dynamics more rather than less concerning.

The NZ$9.6m positive FX translation effect on cash is noted; it is unclear how much of the revenue growth reflects underlying volume and price versus favourable currency translation.

ROE edged down from 14.2% to 13.5%, partly because the equity base is swelling faster than earnings on the back of retained profit and a large cash holding.

Unresolved

• The precise upgraded FY25 guidance range is not disclosed in the extraction packet, making it impossible to judge how demanding the second-half implied task actually is.
• ANZ's revenue decline and margin compression lack a disclosed explanation — is this structural share loss, a deliberate channel-mix shift, or one-off promotional pressure?
• The NZ$66.8m in gross borrowings (up 76.2% from NZ$37.9m) has no associated purpose disclosed; the nature and terms of this facility warrant scrutiny given the company's otherwise ungeared balance sheet.
• FX sensitivity is acknowledged as material but not quantified; given NZ$614m in China-facing revenues, the NZD/CNY and NZD/USD rates are significant swing factors in earnings quality.
• The durability of the English label IMF recovery in China is uncertain: it is unclear whether this reflects genuine channel re-stocking, market share gain, or regulatory re-alignment, any of which would have a different forward trajectory.
• MVM's path to profitability remains uncharted; the segment has improved but the loss has persisted across multiple reporting periods without a disclosed break-even timeline.

This briefing cannot assess the sustainability of the China English label recovery or whether the current revenue acceleration would persist if the NZD strengthened materially against key trading currencies.

Key metrics

Segment breakdown

Analytical metrics

---

This analysis was generated using Annolyse, an AI-powered tool that extracts and analyses NZX/ASX company announcements. The underlying data is extracted from official company filings and verified against source documents. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.